A University of Oxford consortium behind one of the leading vaccine candidates for the coronavirus selected Oxford Biomedica as its lead manufacturer. I was allowed access to photograph at the new OXBOX £20 million facility called Ox Box on the Oxford Business Park. The Jenner Institute at Oxford is currently working on its vaccine candidate with clinical trials about to begin, and Oxford Biomedical is the lead producer should the human trials prove successful. The Oxford vaccine candidate relies on adenoviral vector technology, ChAdOx1, developed at the Jenner Institute, in Oxford. It is seen as one of the most promising vaccine technologies for COVID-19 as ChAdOx1 has been shown to generate a strong immune response from one dose and it has demonstrated a good safety profile in pre-clinical and clinical trials conducted to date. Oxford Biomedica is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.